ALPHAMEDIX: Alpha PRRT with Pb-212 DOTAMTATE in NETs

ALPHAMEDIX - Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients

CLINICALTRIALS.GOV IDENTIFIER: NCT05153772

DRUG/TREATMENT:  AlphaMedix 212Pb-DOTAMTATE 

PHASE:  2

STATUS: Recruiting

SPONSOR: Radiomedix, Inc.  

COLLABORATOR: Orano Med LLC

Dr. Ebrahim Delpassand Discusses the AlphaMedix Trial (May 9, 2023)

Dr. Heloisa Soares Discusses the AlphaMedix Trial (March 10, 2023)

DESCRIPTION:

Radiomedix is sponsoring a multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive). 

In this open-label, multicenter, single-arm Phase 2 study, adult subjects with histologically confirmed NETs and positive somatostatin analog imaging, with no prior PRRT (PRRT naive) will be enrolled to receive 212Pb-DOTAMTATE.

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT:

Susan Cork

EMAIL: scork@exceldiagnostics.com

PHONE: 713-341-3203